ZVRA Q3 2021 Earnings — Zevra Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ZVRAZevra Therapeutics, Inc.

$559M

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+2.1% YoY

Gross Profit

$2M100.0% margin

Operating Income

-$2M-113.1% margin

Net Income

-$2M-89.5% margin

EPS (Diluted)

$-0.05

QoQ Revenue Growth

-83.6%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$620,000

Balance Sheet

Total Assets

$137M

Total Liabilities

$5M

Stockholders' Equity

$132M

Cash & Equivalents

$132M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$2M	+2.1%
Gross Profit	$2M	$2M	+2.1%
Operating Income	-$2M	-$1M	-83.2%
Net Income	-$2M	-$3M	+41.5%